Compare American Financial Group Inc (AFG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs Recursion Pharmaceuticals Inc — how do they compare? American Financial Group Inc trades at $144.75 (market cap $11.97B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: American Financial Group Inc is far larger — about 6.6× Recursion Pharmaceuticals Inc's market cap, and American Financial Group Inc pays a 2.44% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AFG | RXRX | |
|---|---|---|
Market Cap | $11.97B | $1.81B |
Sector | Financials | Health |
52-Week High | $148.71 | $6.79 |
52-Week Low | $124.18 | $2.84 |
Enterprise Value | $12.35B | $1.33B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFG trades at $142.77, down 0.76% on the day, with a bullish technical signal supported by moving averages and a neutral RSI near 59. The stock shows consistent profitability with a net income margin of 11.66% and ROE of 20.41%, though revenue dipped slightly in 2025. Recent Q2 2026 earnings beat estimates, driven by strong P&C underwriting and investment income, as reported by Business Wire on August 4, 2026.
The outlook remains positive with a consensus price target of $160.67, implying 12.5% upside. Risks include potential earnings volatility and competitive pressures in the insurance sector. Analyst sentiment is mixed with 41% buy ratings, but no sell recommendations, supporting a cautiously optimistic view for long-term investors.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
